<DOC>
	<DOC>NCT02712008</DOC>
	<brief_summary>The primary objective of the study is to compare the efficacy of intravitreal (IVT)-administered REGN910-3 compared to intravitreal aflibercept injection (IAI) in improving best corrected visual acuity (BCVA) in patients with diabetic macular edema (DME).</brief_summary>
	<brief_title>Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<criteria>KEY 1. Men or women â‰¥18 years of age with type 1 or type 2 diabetes mellitus who have clinically significant DME with central involvement in the study eye 2. BCVA ETDRS letter score of 73 to 24 (Snellen equivalent of 20/40 to 20/320) in the study eye 3. Willing and able to comply with clinic visits and studyrelated procedures 4. Provide signed informed consent KEY 1. Evidence of macular edema due to any cause other than diabetes mellitus in either eye 2. IVT antiVEGF in the study eye within 12 weeks of the screening visit 3. Panretinal laser photocoagulation or macular laser photocoagulation in the study eye within 3 months of screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>